Please assess the completion status of the following clinical trial:

Trial Title: Erythropoietin in Premature Infants to Prevent Encephalopathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Birthweight less or equal 1500 grams~2. Less than 32 weeks gestation at birth~3. Less than 48 hours of life at time of enrollment~4. Written informed consent of parent or guardian~Exclusion Criteria:~1. Intrauterine Growth Retardation~2. Severe Congenital Anomalies adversely affecting life expectancy or neurodevelopment~3. Genetic Metabolic Diseases~4. Seizures within first 24 hours of life~5. Severe neutropenia (ANC \< 500 cells/microL) within first 24 hours of life~6. Polycythemia (Hct \> 65%) within first 24 hours of life~7. Thrombocytopenia (platelets \< 50K cells/microL) within first 24 hours of life~8. Hypertension (SBP \> 100mmHg) without vasopressor support within first 24 hours of life~9. Microcephaly~10. Grade III-IV intracranial hemorrhage~Termination~1. Required by parent or guardian;~2. Polycythemia through blood transfusion can not be relieved~3. Oliguria（\<0.5mL/kg/h for at least 24 hours）~4. Progression of azotemia~5. Pulmonary hypertension or Cardiac arrhythmia

- Gender: ALL
- Minimum Age: None
- Maximum Age: 48 Hours
- Healthy Volunteers: f

Study Arms:
- Erythropoietin (Type: EXPERIMENTAL): Epo is administered 1000 U/kg, iv in 48 hours after premature birth, and at 48 hours interval for 3 doses per week. After 6 doses, Subcutaneously 3 doses per week until at corrected age of 34 weeks.
- Normal saline (Type: PLACEBO_COMPARATOR): Normal saline is administered 5ml, iv at 3 to 6 hours after premature birth, and at 48 hours interval for 3 doses per week. After 6 doses, Subcutaneously 3 doses per week until at corrected age of 34 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).